Scarica l'app Stockscreener
0.90
0.00%
0.00
Dopo l'orario di chiusura:
.90
Eagle Pharmaceuticals Inc Azioni (EGRX) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
| Data di fine periodo | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 |
| Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
| Revenues |
2.50%
64.65
|
66.31 | 60.70 | 65.90 | 74.14 |
| Cost Of Revenue |
2.55%
16.86
|
17.30 | 18.24 | 20.87 | 21.17 |
| Gross Profit |
2.48%
47.79
|
49.01 | 42.46 | 45.03 | 52.97 |
Operating Expenses
|
0.68%
37.48
|
37.23 | 32.99 | 35.57 | 50.76 |
| Interest Income/Expense |
4.49%
1.448
|
1.516 | 1.98 | 1.147 | 0.552 |
| Benefits Costs and Expenses |
1.29%
55.35
|
56.07 | 47.40 | 69.56 | 80.00 |
| Costs And Expenses |
0.35%
54.34
|
54.53 | 51.23 | 56.44 | 71.93 |
| Operating Income/Loss |
12.48%
10.30
|
11.77 | 9.466 | 9.462 | 2.203 |
| Nonoperating Income/Loss |
34.76%
-1.006
|
-1.542 | 3.838 | -13.12 | -8.071 |
| Income/Loss From Continuing Operations Before Tax |
9.12%
9.298
|
10.23 | 13.30 | -3.663 | -5.868 |
| Income Tax Expense/Benefit |
7.74%
4.134
|
4.481 | 5.139 | 3.468 | 3.582 |
| Income/Loss From Continuing Operations After Tax |
10.19%
5.164
|
5.75 | 8.165 | -7.131 | -9.45 |
|
Net Income/Loss
|
10.19%
5.164
|
5.75 | 8.165 | -7.131 | -9.45 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
0.24%
13.09
|
13.06 | 0.0277 | 13.17 | 12.84 |
| Diluted Average Shares |
0.01%
13.15
|
13.15 | 0.0142 | 13.17 | 12.84 |
| Basic Earnings Per Share |
11.36%
0.39
|
0.44 | 0.63 | -0.54 | -0.74 |
| Diluted Earnings Per Share |
11.36%
0.39
|
0.44 | 0.62 | -0.54 | -0.74 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
0.79%
0.15%
Capitalizzazione:
|
Volume (24 ore):